NCT00182052View on ClinicalTrials.gov

Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2000

Primary Completion Date

August 31, 2003

Study Completion Date

August 31, 2003

Conditions
Adenocarcinoma of the ProstateProstate Cancer
Interventions
DRUG

Rosiglitazone

Given orally twice daily. Participants may continue study treatment as long as their disease does not progress and they don't experience any serious side effects.

OTHER

Placebo

Given orally twice daily.

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

lead

Massachusetts General Hospital

OTHER

NCT00182052 - Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer | Biotech Hunter | Biotech Hunter